Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: December 2013

Chapter 20 - Opioids

from Section 6 - The Management of Neuropathic Pain


Nerve root compression can occur from osteophyte formation, disc herniation, or a combination. As only 1-2% of patients with back pain have a nerve root or spinal cord compression, an accurate diagnosis of the causes of painful radiculopathy relies on a thorough history and physical exam. It is important to note that many asymptomatic individuals have abnormalities such as disc herniations and foraminal stenosis on CT and MRI. Therefore, the imaging findings must be correlated with the history and examination findings. Surgery for spinal stenosis and neurogenic claudication is indicated if severe pain is present, and can provide sustained relief. Since the spinal cord terminates at the L1-2 vertebral level, lumbar pathology below this level may compress the distal nerve root, causing a cauda equina syndrome. A lesion affecting the lumbosacral plexus (LSP) can present with pain in the low back, hip or pelvis, or with sciatica pain.


1. DickensonAH, KiefferB. Opiates: basic mechanisms. In McMahonSB, KoltzenburgM, eds. Wall and Melzack's Textbook of Pain. 5th edition. Philadelphia, PA: Elsevier Churchill Livingstone; 2006, pp. 427–42.
2. SchugSA, GandhamN. Opioids: clinical use. In McMahonSB, KoltzenburgM, eds. Wall and Melzack's Textbook of Pain. 5th edition. Philadelphia, PA: Elsevier Churchill Livingstone; 2006, pp. 443–58.
3. DietisN, RowbothamDJ, LambertDG. Opioid receptor subtypes: fact or artifact?Br J Anaesth 2011;107:8–18.
4. SchoffermanJ, MazanecD. Opioid analgesics. In DagenaisS, HaldermanS, eds. Evidence-based Management of Low Back Pain. St Louis, MI: Elsevier Mosby; 2012, pp. 154–70.
5. SparksDA, FanciulloG. Opioids. In LynchME, CraigKD, PengPWH, editors. Clinical Pain Management: A Practical Guide. Chichester: Wiley-Blackwell; 2011, pp. 128–34.
6. DworkinRH, O'ConnorAB, AudetteJ, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3–14.
7. PierceDM, ShipstoneE. Pharmacology update: tapentadol for neuropathic pain. Am J Hosp Palliat Care 2012;29:663–6.
8. AttalN, Lanteri-MinetM, LaurentB, FermanianJ, BouhassiraD. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain 2011;152:2836–43.
9. DothAH, HanssonPT, JensenMP, TaylorRS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010;149:338–44.
10. MoulinDE, ClarkAJ, GilronI, et al. Pharmacological management of chronic neuropathic pain – consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13–21.
11. FrankB, SerpellMG, HughesJ, MatthewsJN, KapurD. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. Br Med J 2008;336:199–201.
12. HarkeH, GretenkortP, LadleifHU, RahmanS, HarkeO. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. Anesth Analg 2001;92:488–95.
13. SindrupSH, AndersenG, MadsenC, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999;83:85–90.
14. WatsonCP, MoulinD, Watt-WatsonJ, GordonA, EisenhofferJ. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71–8.
15. HaratiY, GoochC, SwensonM, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842–6.
16. WatsonCP, BabulN. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837–41.
17. GobelH, StadlerTH. Treatment of pain due to postherpetic neuralgia with tramadol. Results of an open, parallel pilot study vs clomipramine with and without levomepromazine. Clin Drug Invest 1995;10:208–14.
18. RajaSN, HaythornthwaiteJA, PappagalloM, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015–21.
19. BoureauF, LegallicierP, Kabir-AhmadiM. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003;104:323–31.
20. GimbelJS, RichardsP, PortenoyRK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60:927–34.
21. HuseE, LarbigW, FlorH, BirbaumerN. The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001;90:47–55.
22. GilronI, BaileyJM, TuD, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324–34.
23. KhoromiS, CuiL, NackersL, MaxMB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007;130:66–75.
24. NorrbrinkC, LundebergT. Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Clin J Pain 2009;25:177–84.
25. SimpsonDM, MessinaJ, XieF, HaleM. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:588–601.
26. WuCL, AgarwalS, TellaPK, et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Anesthesiology 2008;109:289–96.
27. HannaM, O'BrienC, WilsonMC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12:804–13.
28. ZinCS, NissenLM, O'CallaghanJP, et al. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain 2010;11:462–71.
29. SchwartzS, EtropolskiM, ShapiroDY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27:151–62.
30. EisenbergE, McNicolE, CarrDB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146.
31. FinnerupNB, SindrupSH, JensenTS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573–81.
32. FurlanA, ChaparroLE, IrvinE, Mailis-GagnonA. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag 2011;16:337–51.
33. O'ConnorAB, DworkinRH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122:S22–32.
34. BrilV, EnglandJ, FranklinGM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758–65. Erratum 2011;77:603.
35. McNicolE, BoyceDB, SchumannR, CarrD. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med 2008;9:634–59.
36. MaoJ. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002;100:213–17.
37. RamasubbuC, GuptaA. Pharmacological treatment of opioid-induced hyperalgesia: a review of the evidence. J Pain Palliat Care Pharmacother 2011;25:219–30.
38. DaniellHW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3:377–84.
39. DaniellHW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 2008;9:28–36.
40. VestergaardP, RejnmarkL, MosekildeL. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006;260:76–87.
41. CleggA, YoungJB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing 2011;40:23–9.
42. KahanM, WilsonL, Mailis-GagnonA, SrivastavaA. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician 2011;57:1269–76.
43. KingS, ForbesK, HanksGW, FerroCJ, ChambersEJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011;25:525–52.
44. National Opioid Use Guideline Group (NOUGG). Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. Available from: http://nationalpaincentre mcmaster ca/opioid/. 2010.
45. BondGR, HoM, WoodwardRW. Trends in hepatic injury associated with unintentional overdose of paracetamol (acetaminophen) in products with and without opioid: an analysis using the National Poison Data System of the American Association of Poison Control Centers, 2000–7. Drug Safety 2012;35:149–57.
46. GuilleminaultC, CaoM, YueHJ, ChawlaP. Obstructive sleep apnea and chronic opioid use. Lung 2010;188:459–68.
47. WalkerJM, FarneyRJ. Are opioids associated with sleep apnea? A review of the evidence. Curr Pain Headache Rep 2009;13(2):120–6.
48. ZgierskaA, BrownRT, ZuelsdorffM, et al. Sleep and daytime sleepiness problems among patients with chronic noncancerous pain receiving long-term opioid therapy: a cross-sectional study. J Opioid Manag 2007;3:317–27.
49. FishbainDA, ColeB, LewisJ, RosomoffHL, RosomoffRS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9:444–59.
50. WebsterLR, WebsterRM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432–42.
51. StarrelsJL, BeckerWC, AlfordDP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 2010;152:712–20.
52. ChristoPJ, ManchikantiL, RuanX, et al. Urine drug testing in chronic pain. Pain Physician 2011;14:123–43.
53. FurlanAD, ReardonR, SalachL. The opioid manager: a point-of-care tool to facilitate the use of the Canadian Opioid Guideline. J Opioid Manag 2012;8:57–61.